GlobalData completes fourth acquisition in its second half

GlobalData announced the completion of its acquisition of Deallus, a competitive intelligence solutions provider specialising in the global life sciences sector, on Tuesday.

The AIM-traded firm said the transaction, finalised on 31 December, was a significant step in its strategy to expand its offerings within the healthcare division.

Deallus, with two decades of expertise, was focussed on key therapy areas such as oncology, neuroscience, vaccines, rare diseases, cell and gene therapies, and immunology.

The board said the acquisition would enhance GlobalData’s ability to foster deeper relationships with major pharmaceutical brands, and to provide more comprehensive insights and value to clients in the life sciences sector.

It was the fourth acquisition GlobalData completed in the second half of 2024, alongside Business Trade Media International, LinkUp, and Celent.

All transactions were supported by the group’s recently-announced debt facilities.

GlobalData said it planned to provide further details on the impact of its recent acquisition activity during its trading update and 2024 results announcement on 14 January.

“This acquisition further enhances our capabilities in delivering life sciences solutions, allowing us to deliver even more comprehensive insights and services to our clients,” said chief executive officer Mike Danson.

“Deallus's deep sector expertise and client-first mindset perfectly align with our mission to empower decision-makers in navigating the complexities of the healthcare landscape.

“Together, we are poised to drive remarkable growth and deliver exceptional value to our stakeholders.”

At 1229 GMT, shares in GlobalData were up 2.97% at 208p.

Reporting by Josh White for Sharecast.com.